Bryan Johnson Longevity Protocol: How a Regular Patient Gets Access

Who Is Bryan Johnson and What Is Blueprint?

Bryan Johnson is the founder of Braintree (acquired by PayPal for $800 million in 2013) and OS Fund. Since roughly 2021 he has redirected a significant portion of his resources toward a self-experimentation longevity project he calls Blueprint. The stated goal is to slow or reverse biological aging across every measurable organ system.

Blueprint is not proprietary in the commercial sense. Johnson publishes his full protocol, bloodwork, and testing results publicly at blueprint.bryanjohnson.co and across his social channels. That transparency is genuinely useful for patients and clinicians who want to evaluate what the evidence actually supports.

What the Protocol Covers

Blueprint spans five domains: nutrition (a whole-food, mostly vegan diet with precise caloric targets), sleep (strict 8.5-hour schedule, no evening light), exercise (one hour daily combining resistance and zone-2 cardio), biomarker monitoring (dozens of quarterly labs), and pharmacology (prescription drugs plus supplements). This article focuses on the pharmacological layer because that is where regular patients most often ask whether access is realistic.

How Johnson Measures Progress

Johnson tracks biological age using validated algorithms including the Levine PhenoAge clock, the DunedinPACE epigenetic clock, and organ-specific imaging. In a 2023 update published on his website and corroborated by his physician Dr. Oliver Zolman, Johnson reported a DunedinPACE score of 0.69, meaning his epigenome ages roughly 31% more slowly than a typical adult of his chronological age. Independent replication of individual n=1 results is not possible, but the measurement tools themselves are validated in population studies. The 2022 paper by Belsky et al. In eLife validated DunedinPACE in the Dunedin Cohort of 1,037 participants. [1]

The Full Prescription Drug Stack Johnson Has Disclosed

Johnson has publicly named the following prescription drugs across interviews, his website, and podcasts including Huberman Lab and Lex Fridman's show. This is a summary of what he has confirmed, not an inferred list.

Metformin

Metformin 1,500 to 1,800 mg/day (extended-release) is one of the most frequently cited longevity drugs in the literature. Johnson takes it primarily for its AMPK-activating and mTORC1-inhibiting effects. The TAME trial (Targeting Aging with Metformin), a randomized, placebo-controlled trial currently enrolling ~3,000 adults aged 65 to 79 at 14 US sites, is the first FDA-approved clinical trial to test a drug against aging itself as a primary endpoint. The NIH National Institute on Aging is co-funding TAME; see the trial overview at NIA.NIH.gov. [2]

Metformin is FDA-approved for type 2 diabetes and is prescribed off-label for longevity, PCOS, and metabolic optimization. It costs roughly $10, $25/month at most pharmacies and is accessible through any telehealth provider with prescribing authority in your state.

One important caution: a 2022 meta-analysis in the British Journal of Sports Medicine (N=5 RCTs, 268 participants) found metformin may blunt skeletal muscle adaptations to resistance training in older adults, a concern directly relevant to anyone combining it with an exercise-focused longevity protocol. 2b [3]

Low-Dose Rapamycin

Rapamycin (sirolimus) is the drug most longevity physicians describe as the closest thing to a confirmed aging-slowing compound in mammals. The Interventions Testing Program run by the NIA found rapamycin extended median lifespan by 9 to 14% in multiple cohorts of genetically heterogeneous mice, even when initiated at an age equivalent to 60 years in humans. [See the ITP compound list at NIA NIH.gov.] [2]

Johnson takes rapamycin approximately 6 mg once weekly. This intermittent dosing schedule is used to minimize immunosuppressive effects while preserving mTOR inhibition cycles. Rapamycin is FDA-approved for organ transplant rejection prevention. Off-label longevity use requires a physician willing to prescribe it, and not all states or telehealth platforms support this. Specialist longevity clinics and some compounding-pharmacy-connected providers do prescribe it. Monitoring includes fasting lipids (rapamycin can raise triglycerides) and periodic CBC.

Acarbose

Acarbose 200 mg with meals is an alpha-glucosidase inhibitor FDA-approved for type 2 diabetes. In the NIA Interventions Testing Program, acarbose extended median lifespan by 22% in male mice and 5% in female mice. [2] Johnson uses it to blunt post-meal glucose spikes, a strategy consistent with continuous glucose monitor data he shares publicly. Acarbose is accessible through diabetes-focused telehealth platforms when metabolic indications are present.

Testosterone and DHEA

Johnson was testosterone-deficient at baseline (he has stated this publicly) and uses testosterone therapy along with DHEA supplementation. Testosterone replacement therapy (TRT) for documented hypogonadism is FDA-approved and widely available through telehealth. A 2023 New England Journal of Medicine paper (TRAVERSE trial, N=5,246 men aged 45 to 80 with hypogonadism and elevated cardiovascular risk) found testosterone treatment was non-inferior to placebo for major adverse cardiac events over a mean 33 months of follow-up. 4

DHEA 25 to 50 mg/day is available over the counter in the US, though prescription DHEA (FDA-approved Intrarosa for vaginal atrophy) also exists. Johnson targets specific serum DHEA-sulfate levels and adjusts dosing with labs.

Other Disclosed Rx Agents

Johnson has also referenced thyroid hormone optimization (T3/T4 titration to specific free-hormone targets), low-dose lithium orotate (for neuroprotective effects, though evidence remains preliminary in humans), and occasional use of growth hormone secretagogues. Each of these carries distinct prescribing requirements and safety profiles that should be reviewed with a clinician before initiation.

The Supplement Stack: What Is Evidence-Backed Versus Theoretical

Johnson's publicly posted supplement list runs past 100 items. Evaluating every compound is outside the scope of this article, but the following have the strongest human-grade evidence and appear consistently in his protocol.

Supplements With Meaningful Human Trial Data

NMN or NR (NAD+ precursors): A 2023 randomized trial published in Nature Aging (N=30, 12-week duration) found NMN 300 mg/day increased whole-blood NAD+ concentrations by a mean of 38% vs. Placebo (P<0.001) in healthy middle-aged adults. Whether elevated NAD+ translates to functional aging outcomes in humans remains an open question. 5

Omega-3 fatty acids: The REDUCE-IT trial (N=8,179) found icosapentaenoic acid (EPA) 4 g/day reduced major cardiovascular events by 25% vs. Mineral oil placebo in patients with elevated triglycerides on statins. 6 Johnson uses high-dose fish oil targeting specific EPA/DHA plasma levels.

Vitamin D3 + K2: Johnson targets 25-OH vitamin D serum levels of 60 to 80 ng/mL, above the standard sufficiency cutoff of 30 ng/mL. Whether supranormal vitamin D confers additional benefit is debated. The VITAL trial (N=25,871) found vitamin D3 2,000 IU/day did not reduce incident cancer or cardiovascular events vs. Placebo in the primary analysis, though a pre-specified analysis showed reduced cancer mortality after 2 years. 7

Berberine: Mechanistically similar to metformin (AMPK activation, gut microbiome modulation). Johnson includes it partly as a complement to acarbose for glucose control.

Supplements With Mostly Preclinical Support

Several compounds Johnson takes, including spermidine, fisetin, quercetin, and high-dose lithium orotate, have compelling mouse-model or cell-line data but limited randomized human trial evidence as of early 2025. Johnson acknowledges this openly. His position, stated in a 2023 interview with the Huberman Lab podcast, is that the theoretical risk/benefit at these doses is acceptable given preclinical data, but he is explicit that he is self-experimenting and that others should not simply copy his stack without medical guidance.

How a Regular Patient Builds a Supervised Equivalent

This is the practical center of the article. Johnson spends $2 million per year largely because he employs a full-time medical team, runs MRI imaging quarterly, and pays for research-grade testing. None of that infrastructure is required to access the pharmacological core of his protocol.

The following tiered framework reflects what is clinically accessible and medically appropriate for a healthy adult with no contraindications, organized by cost and complexity.

Tier 1: Accessible Through Standard Telehealth (Month 1)

These are either FDA-approved drugs with established off-label longevity use or OTC supplements with solid human data. Total estimated monthly cost: $150, $250 including labs.

1. Comprehensive baseline labs: Fasting metabolic panel, CBC, HbA1c, fasting insulin, lipid panel with ApoB, free and total testosterone (all sexes), DHEA-S, free T3/T4, TSH, 25-OH vitamin D, hsCRP, homocysteine. Without this baseline, no prescriber can responsibly initiate any of the following.
2. Metformin ER 500 to 1,000 mg/day (titrate up over 4 weeks to reduce GI side effects): accessible via any telehealth platform with metabolic-health prescribers. Requires HbA1c and renal function check (eGFR >45 ml/min/1.73m² is the standard threshold per the FDA label).(https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020357s037s039,021202s021s023lbl.pdf) [8]
3. Testosterone therapy if labs confirm hypogonadism (total testosterone <300 ng/dL per Endocrine Society guidelines 9): available through HealthRX and most TRT telehealth platforms.
4. High-dose omega-3s targeting EPA+DHA >2 g/day: OTC or prescription icosapentaenoic acid.
5. Vitamin D3 2,000 to 5,000 IU/day with K2 100 to 200 mcg/day: OTC, dose adjusted to serum level.
6. NMN or NR 300 to 500 mg/day: OTC.

Tier 2: Requires Longevity-Focused Specialist (Month 2 to 3)

These are drugs that require a clinician familiar with off-label longevity prescribing, not a generalist. Cost adds $100, $200/month to Tier 1.

1. Low-dose rapamycin 5 to 6 mg once weekly: Obtainable through specialist longevity clinics or telehealth platforms with longevity-trained MDs. Requires baseline fasting lipids and CBC; recheck at 3 months. The AgeMD and similar platforms advertise this.
2. Acarbose 25 to 100 mg with meals: Accessible through metabolic telehealth platforms, especially if post-meal glucose data (CGM) supports use.
3. DHEA 25 to 50 mg/day (prescription or OTC): Confirm serum DHEA-S at baseline.

Tier 3: Research-Grade and Emerging (Month 3+)

Compounds like NAD+ IV infusions, senolytics (dasatinib plus quercetin pulsing), and growth hormone secretagogues like ipamorelin or tesamorelin require specialized oversight, carry higher cost ($300, $1,000+/month), and have substantially less human safety data. Johnson uses some of these but contextualizes them as experimental. HealthRX's medical team reviews each case individually before these are considered.

What the Evidence Says About the Longevity Drug Cluster as a Whole

No randomized trial has tested this exact combination in humans. That is the honest position. What exists is:

• Strong mechanistic convergence: metformin, rapamycin, and acarbose all modulate mTOR and/or AMPK signaling, the pathways most consistently linked to lifespan extension in model organisms. [A 2021 review in Cell Metabolism by López-Otín et al. Documented 12 hallmarks of aging with direct mechanistic overlap with these drug targets.] 10
• Ongoing human trials: TAME (metformin), the Interventions Testing Program, and multiple rapamycin trials in older adults (PEARL trial, NCT04488601) are building the evidence base. 11
• Real safety signals: Metformin-exercise antagonism, rapamycin-induced dyslipidemia, and potential male fertility effects of rapamycin are not theoretical. They require monitoring.

As Dr. Nir Barzilai, principal investigator of the TAME trial, stated in a 2023 interview with STAT News: "We're not saying metformin cures aging. We're saying it's the first molecule where we have enough evidence to test whether targeting aging as a process is a viable medical strategy." That framing is the right one for patients evaluating whether any part of this protocol belongs in their own care plan.

Safety, Contraindications, and Who Should Not Pursue This Protocol

Some patients should not pursue off-label longevity pharmacology without careful specialist review. These include individuals with:

• Chronic kidney disease stage 3b or worse (eGFR <45): metformin is contraindicated.
• Active malignancy or immunodeficiency: rapamycin has meaningful immunosuppressive effects at longevity doses; risk-benefit requires oncology input.
• Liver disease: multiple drugs in this stack are hepatically metabolized.
• Pregnancy or planned pregnancy within 12 months: rapamycin is teratogenic; metformin has FDA Pregnancy Category B status but is not indicated for non-diabetic pregnant patients; testosterone is absolutely contraindicated.
• Age <30 without documented deficiency: the evidence base for these drugs in young, otherwise healthy adults without metabolic disease is essentially absent.

The Endocrine Society's 2019 clinical practice guideline on male hypogonadism explicitly states: "We recommend against testosterone therapy in men who desire fertility in the near term." [9] That guidance applies equally to patients considering testosterone as part of a longevity stack rather than for symptomatic hypogonadism.

The Cost Question: What Does a Realistic Version Actually Cost?

Johnson's $2 million figure includes a private physician on salary, quarterly MRI scans of the brain, heart, and abdomen, continuous EEG sleep monitoring, and proprietary research investments. None of that is necessary to access the pharmacological tier.

A realistic supervised protocol through a US telehealth platform covering Tier 1 items runs:

• Baseline labs: $200, $400 (one-time, or annually)
• Metformin ER: $10, $25/month
• TRT (if indicated): $80, $200/month depending on formulation
• Omega-3 prescription (Vascepa/generic EPA): $30, $80/month with insurance
• Supplements (D3/K2, NMN): $40, $80/month
• Telehealth consultation: $100, $200/visit, typically quarterly once stable

Total first-year cost: roughly $3,000, $6,000 including labs. That is 0.15 to 0.3% of Johnson's spend for access to the evidence-backed core of what he takes.